US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

ホーム
投資
株式
アメリカ
NASDAQ
Kiniksa Pharmaceuticals International PLC (KNSA)
Kiniksa Pharmaceuticals International PLC (KNSA) ニュース

Kiniksa Pharmaceuticals International PLC (KNSA)

48.42

-0.81

(-1.65%)

終了 6月7日 5:00AM

48.42

0.045

(0.09%)

取引時間後: 8:59AM

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

Form 8-K - Current report

Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences

LONDON, May 29, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today...

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution

– ARCALYST® (rilonacept) Q1 2026 net product revenue of $214.3 million, representing 56% year-over-year growth...

Kiniksa Pharmaceuticals to Report First Quarter 2026 Financial Results on April 28, 2026

LONDON, April 23, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA...

Form ARS - Annual Report to Security Holders

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form DEF 14A - Other definitive proxy statements

Form 4 - Statement of changes in beneficial ownership of securities

Monksdream

Monksdream 2年前

KNSA inching back up

DonDonDonDon

DonDonDonDon 5年前

No bueno. I guess HGEN's lenzilumab is the best of the anti-GM-CSF drugs for Covid. Lenzilumab's trial showed 54% efficacy. It is guaranteed an EUA within a couple of weeks yet its stock is 20% below where it was a month ago. It dropped 2 days ago because they diluted 5 million shares to pay for manufacturing.

https://www.rheumatologyadvisor.com/home/general-rheumatology/mavrilimumab-outcomes-patients-with-severe-covid19-pneumonia-hyperinflammation/

DonDonDonDon

DonDonDonDon 5年前

It was recently discovered that the protein GM-CSF is the cytokine responsible for severe Covid and death. Kiniksa will surely get a government grant to do an additional trial. Here is a BBC article about the trial that determined that GM-CSF is key to Covid:

https://www.bbc.com/news/health-56352128

Here is an additional article stating that KNSA and HGEN are the two companies with the best GM-CSF drugs to combat Covid:

https://www.clinicaltrialsarena.com/comment/humanigens-and-kiniksas-anti-gm-csf-antibodies-likely-to-garner-a-place-for-nonventilated-covid-19-patients/

Femto99

Femto99 5年前

PT= $30-40 (by or around March 31st)
https://msmoneymoves.com/2021/02/17/knsa-report/

Femto99

Femto99 5年前

Kiniksa Pharmaceuticals

Cleveland Cliffs

PGIM S&P 500 Buffer 20 E...

MSCI Fintech Innovation ...

Catheter Precision

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。